Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients

European Journal of Cancer

Volumn 71, Issue , 2017, Pages 43-50

  Sartore Bianchi, Andrea ^a   Pietrantonio, Filippo ^b   Amatu, Alessio ^a   Milione, Massimo ^b   Cassingena, Andrea ^a   Ghezzi, Silvia ^a   Caporale, Marta ^b   Berenato, Rosa ^b   Falcomatà, Chiara ^c,d   Pellegrinelli, Alessio ^b   Bardelli, Alberto ^c,d   Tosi, Federica ^a   De Braud, Filippo ^b   Di Nicolantonio, Federica ^c,d   Barault, Ludovic ^c,d   Siena, Salvatore ^a,e  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Alkylating agent; Digital PCR; DNA methylation; Immunohistochemistry; Metastatic colorectal cancer; MGMT

Indexed keywords

BIOLOGICAL MARKER; DACARBAZINE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DNA METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; DIGITAL POLYMERASE CHAIN REACTION; DNA EXTRACTION; DNA METHYLATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROCEDURES; SECONDARY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85006263446     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.032     Document Type: Article

References (20)

1. [1] Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S.N., Hidalgo, O.F., Vanaclocha, V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:19 (2000), 1350–1354.
2. [2] Esteller, M., Herman, J.G., Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1 (2004), 1–8.
3. [3] Esteller, M., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M.A., Watkins, D.N., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:9 (2000), 2368–2371.
4. [4] Ju, H.X., An, B., Okamoto, Y., Shinjo, K., Kanemitsu, Y., Komori, K., et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol 178:4 (2011), 1835–1846.
5. [5] Barault, L., Amatu, A., Bleeker, F.E., Moutinho, C., Falcomata, C., Fiano, V., et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol 26:9 (2015), 1994–1999.
6. [6] Shima, K., Morikawa, T., Baba, Y., Nosho, K., Suzuki, M., Yamauchi, M., et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22:2 (2011), 301–309.
7. [7] Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:10 (2005), 997–1003.
8. [8] Tuominen, R., Jewell, R., van den Oord, J.J., Wolter, P., Stierner, U., Lindholm, C., et al. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer 136:12 (2015), 2844–2853.
9. [9] Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K., Ghezzi, S., et al. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann Oncol 27:6 (2016), 1062–1067.
10. [10] Amatu, A., Sartore-Bianchi, A., Moutinho, C., Belotti, A., Bencardino, K., Chirico, G., et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 19:8 (2013), 2265–2272.
11. [11] Hochhauser, D., Glynne-Jones, R., Potter, V., Gravalos, C., Doyle, T.J., Pathiraja, K., et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 12:5 (2013), 809–818.
12. [12] Pietrantonio, F., de Braud, F., Milione, M., Maggi, C., Iacovelli, R., Dotti, K.F., et al. Dose-dense temozolomide in patients with MGMT-silenced chemorefractory colorectal cancer. Target Oncol 11:3 (2016), 337–343.
13. [13] Pietrantonio, F., Perrone, F., de Braud, F., Castano, A., Maggi, C., Bossi, I., et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 25:2 (2014), 404–408.
14. [14] Miyazaki, M., Nishihara, H., Terasaka, S., Kobayashi, H., Yamaguchi, S., Ito, T., et al. Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma. Neuropathology 34:3 (2014), 268–276.
15. [15] Lalezari, S., Chou, A.P., Tran, A., Solis, O.E., Khanlou, N., Chen, W., et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 15:3 (2013), 370–381.
16. [16] Castillo-Martin, M., Thin, T.H., Collazo Lorduy, A., Cordon-Cardo, C., Immunopathologic assessment of PTEN expression. Methods Mol Biol 1388 (2016), 23–37.
17. [17] Ilie, M.I., Bence, C., Hofman, V., Long-Mira, E., Butori, C., Bouhlel, L., et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 26:1 (2015), 238–244.
18. [18] Shen, L., Kondo, Y., Rosner, G.L., Xiao, L., Hernandez, N.S., Vilaythong, J., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97:18 (2005), 1330–1338.
19. [19] Zhang, L., Zeng, J., Zeng, Z., Wang, F., Wang, D., Chen, C., et al. MGMT in colorectal cancer: a promising component of personalized treatment. Tumour Biol 37:8 (2016), 11443–11456.
20. [20] Zhao, W., Soejima, H., Higashimoto, K., Nakagawachi, T., Urano, T., Kudo, S., et al. The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 137:3 (2005), 431–440.